CHEChemed Corp

Ticker: CHE | Filing Type: 8-K (Items 2.02, 9.01) | Filed with the SEC: October 27, 2026 | Current Price: $549.10 (+7.86% today)

---

What Happened

Chemed Corp filed an 8-K with the SEC on October 27, 2026 disclosing its second-quarter FY2026 financial results. The company reported total revenues of $1.265 billion, operating income of $162.8 million, and net income of $124.3 million for the quarter. Diluted earnings per share came in at $8.43, with basic EPS at $8.51, reflecting the profitability generated across Chemed's operating segments during the period.

---

Why It Matters

For investors, the headline numbers represent a substantial revenue base for a healthcare services operator, and the combination of a $162.8 million operating result alongside $124.3 million in net income signals that margins are holding at a meaningful level. The stock's move of nearly +7.86% on the day of reporting strongly suggests the market interpreted these results as a positive surprise relative to expectations. Diluted EPS of $8.43 in a single quarter is a notable data point for assessing the company's annualised earnings power and its ability to generate consistent shareholder returns.

---

Analysis

The Q2 FY2026 results present a picture of a company generating significant operating cash conversion, with operating income of $162.8 million on revenues of $1.265 billion implying an operating margin in the vicinity of 12.9%. The gap between basic ($8.51) and diluted ($8.43) EPS is modest, suggesting limited dilution from share-based compensation or convertible instruments.

The near 8% single-session price gain is an unusually large move for an established healthcare services name and indicates the results cleared a meaningful expectations hurdle. Investors will want to monitor whether this top-line momentum is sustainable across coming quarters and whether operating leverage continues to translate efficiently into bottom-line earnings. For context, the filing also references contract revenue of approximately $1.202 billion for FY2024, which provides a useful prior-period anchor for gauging the revenue trajectory.

StockWatch published its initiating coverage on Chemed on October 28, 2026 — investors looking for deeper fundamental context and a full investment framework around these results should refer to that research directly.

Key items to watch going forward:

• Revenue trajectory — whether quarterly revenues can sustain or grow beyond the $1.265B level
• Margin stability — operating margin and net margin trends across segments
• EPS progression — whether diluted EPS continues at or above current quarter levels on an annualised basis
• Capital allocation — buybacks, dividends, or acquisitions that may affect share count and per-share metrics

---

Disclaimer

This report is a news and informational analysis based solely on data contained in Chemed Corp's SEC filing dated October 27, 2026, and publicly available pricing information. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. No rating or price target is assigned herein. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Existing Coverage

StockWatch has full coverage on CHE, published 2026-10-28. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-27. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/19584/000001958426000022/che-20261027x8k.htm